沈慧勇:术中放疗新技术减少脊柱骨盆肿瘤患者手术风险

2013-09-16 佚名 深圳特区报

最近,中山大学孙逸仙纪念医院成功完成华南地区首例脊柱骨盆肿瘤患者术中放疗新技术。 该院院长、骨外科主任沈慧勇教授组织专家成立术中放疗小组进行深入研究探讨,并带领脊柱骨盆肿瘤手术团队,经麻醉科、手术室、放疗科及技术人员的通力合作,在为骶骨转移癌的患者进行骶骨肿瘤整块切除后,实施术中放疗,整个治疗过程非常顺利,患者平稳返回病房,术后恢复理想。 脊柱是全身多种癌转移的

最近,中山大学孙逸仙纪念医院成功完成华南地区首例脊柱骨盆肿瘤患者术中放疗新技术。

该院院长、骨外科主任沈慧勇教授组织专家成立术中放疗小组进行深入研究探讨,并带领脊柱骨盆肿瘤手术团队,经麻醉科、手术室、放疗科及技术人员的通力合作,在为骶骨转移癌的患者进行骶骨肿瘤整块切除后,实施术中放疗,整个治疗过程非常顺利,患者平稳返回病房,术后恢复理想。

脊柱是全身多种癌转移的好发部位,在患肿瘤的病人中,有40%—80%出现骨转移。沈慧勇介绍, 统计显示,脊柱转移的病人20%以上有神经损害,75%的骨转移发生于乳腺癌、肺癌、肾癌、前列腺癌、甲状腺癌和多发性骨髓瘤的病人。因此,如何有效治疗癌细胞脊柱转移,对于提高癌症患者的生存率非常重要。他说,脊柱骨盆肿瘤结构解剖的特殊性,恶性肿瘤完整切除较为困难,局部面临复发的高风险。所以,以往很多患者一知道骨转移就有放弃治疗的想法。其实是非常错误的,骨转移瘤的出现并不总是癌症终末期的“宣判”。实际上,结合原发肿瘤的病理类型,对合适的病例进行脊柱转移癌手术、放疗、化疗、生物治疗等综合治疗,不但可以及时缓解疼痛,还可以“带瘤”长期存活。

沈慧勇指出,在预防复发方面,以往临床医师常通过术后辅助性放射治疗进行弥补,但有一定的局限性。近年来,一种新的术中放射治疗技术Intrabeam逐渐开始在临床上应用,可以直接、精确定位瘤床和需要照射的区域,直接杀伤手术区域残留的癌细胞,显著降低局部的复发率,也可以最大限度地保护正常组织免受或少受不必要的照射,减少放射治疗的副作用。此外,以往传统术中放疗系统通常是在放疗科进行,放疗设备笨重,不能精确定位瘤床,周围组织损害严重,放疗后,患者还须经过长途搬运才能到手术室手术。而新术中放疗系统是经改进的手术室专用的电子束直线加速器,无特殊放射防护要求,患者可在手术室直接进行放疗,避免从放疗室接受术中放疗后再运回手术室完成手术,减少手术风险。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=274778, encodeId=181f2e4778f8, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Jan 02 15:44:05 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903657, encodeId=99c5190365e6b, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Wed Mar 12 04:03:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424129, encodeId=22af14241293c, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Wed Sep 18 00:03:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548434, encodeId=d7a11548434f9, content=<a href='/topic/show?id=860c545197f' target=_blank style='color:#2F92EE;'>#手术风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54519, encryptionId=860c545197f, topicName=手术风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c8f14082259, createdName=huagfeg, createdTime=Wed Sep 18 00:03:00 CST 2013, time=2013-09-18, status=1, ipAttribution=)]
    2018-01-02 1e145228m78(暂无匿称)

    学习了谢谢作者分享!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=274778, encodeId=181f2e4778f8, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Jan 02 15:44:05 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903657, encodeId=99c5190365e6b, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Wed Mar 12 04:03:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424129, encodeId=22af14241293c, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Wed Sep 18 00:03:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548434, encodeId=d7a11548434f9, content=<a href='/topic/show?id=860c545197f' target=_blank style='color:#2F92EE;'>#手术风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54519, encryptionId=860c545197f, topicName=手术风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c8f14082259, createdName=huagfeg, createdTime=Wed Sep 18 00:03:00 CST 2013, time=2013-09-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=274778, encodeId=181f2e4778f8, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Jan 02 15:44:05 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903657, encodeId=99c5190365e6b, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Wed Mar 12 04:03:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424129, encodeId=22af14241293c, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Wed Sep 18 00:03:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548434, encodeId=d7a11548434f9, content=<a href='/topic/show?id=860c545197f' target=_blank style='color:#2F92EE;'>#手术风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54519, encryptionId=860c545197f, topicName=手术风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c8f14082259, createdName=huagfeg, createdTime=Wed Sep 18 00:03:00 CST 2013, time=2013-09-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=274778, encodeId=181f2e4778f8, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Jan 02 15:44:05 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903657, encodeId=99c5190365e6b, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Wed Mar 12 04:03:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424129, encodeId=22af14241293c, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Wed Sep 18 00:03:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548434, encodeId=d7a11548434f9, content=<a href='/topic/show?id=860c545197f' target=_blank style='color:#2F92EE;'>#手术风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54519, encryptionId=860c545197f, topicName=手术风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c8f14082259, createdName=huagfeg, createdTime=Wed Sep 18 00:03:00 CST 2013, time=2013-09-18, status=1, ipAttribution=)]